SK

Sumit Kumar

Director Director DIN 06679131
DIN 06679131 First appointment Nov 2013 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Nov 2013
Shareholding value β€’β€’β€’β€’ Premium profile

About Sumit Kumar

Data last updated:

Sumit Kumar was a Director at Ivy Nelson Pharmaceuticals Private Limited (2013–2019) and Director at Gmelina Pharmaceuticals Private Limited (from 2014). The companies operate in Pharma.

DIN 06679131
Primary Designation Director
Industry Pharma
First Appointment 28 Nov 2013
Oldest Company Age 12 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director28 Nov 20132013₹19.5 Lakh (FY 2019)Strike Off
Director03 Jan 20142014Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Gmelina Pharmaceuticals Private Limited
Ivy Nelson Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Sumit Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sumit Kumar

Sumit Kumar was first appointed on 28 Nov 2013 as Director at Ivy Nelson Pharmaceuticals Private Limited. The most recent appointment on record is 03 Jan 2014 at Gmelina Pharmaceuticals Private Limited.

Sumit Kumar held 2 earlier board appointments: Ivy Nelson Pharmaceuticals Private Limited (Director, 28 Nov 2013 to 05 Sep 2019); Gmelina Pharmaceuticals Private Limited (Director, from 03 Jan 2014).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available